Cyclerion Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cyclerion Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.07M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $2.00M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Nov 12, 2025 |
| FY2023 | Dec 31, 2022 | $297.0K | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $3.94M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $2.30M | Feb 24, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $2.30M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $4.51M | Feb 25, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.53M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($3.06M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($5.26M) | Nov 12, 2025 |
| FY2023 | Dec 31, 2022 | ($44.08M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($51.65M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($77.80M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($123.01M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($115.25M) | Mar 12, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.97M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($3.63M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($12.95M) | Nov 12, 2025 |
| FY2023 | Dec 31, 2022 | ($18.54M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($55.20M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($81.27M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($125.04M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($115.25M) | Mar 12, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $959.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $286.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $1.52M | Nov 12, 2025 |
| FY2023 | Dec 31, 2022 | $5.98M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $37.64M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $56.41M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $95.14M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $87.72M | Mar 12, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.31M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($4.33M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($21.25M) | Nov 12, 2025 |
| FY2023 | Dec 31, 2022 | ($40.61M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($36.52M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($72.49M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($102.22M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($97.50M) | Mar 12, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $0 | Mar 22, 2023 |
| FY2022 | Dec 31, 2021 | $7.0K | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $1.52M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $6.89M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $3.44M | Mar 12, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.99M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $9.58M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $13.37M | Nov 12, 2025 |
| FY2023 | Dec 31, 2022 | $18.08M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $59.33M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $115.38M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $186.48M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $7.40M | Mar 12, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.09M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $8.85M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $11.29M | Nov 12, 2025 |
| FY2024 | Dec 31, 2022 | $10.45M | Mar 4, 2025 |
| FY2023 | Dec 31, 2021 | $48.25M | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | $59.49M | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | $97.73M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($10.45M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($8.57M) | Mar 12, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($271.02M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($267.49M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($264.42M) | Nov 12, 2025 |
| FY2023 | Dec 31, 2022 | ($259.15M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($215.08M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($163.43M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($85.63M) | Feb 25, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.24M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $3.23M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $7.57M | Nov 12, 2025 |
| FY2023 | Dec 31, 2022 | $13.38M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $53.96M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $54.40M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $94.90M | Feb 25, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Nov 12, 2025 |
| FY2023 | Dec 31, 2022 | (20) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 22, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Nov 12, 2025 |
| FY2023 | Dec 31, 2022 | (20) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 22, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.82M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 2.55M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 2.47M | Nov 12, 2025 |
| FY2023 | Dec 31, 2022 | 2.18M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | 43.41M | Mar 22, 2023 |
| FY2020 | Dec 31, 2020 | 34.05M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | 27.60M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 12, 2020 |